Item 2.02. Results of Operations and Financial Condition.

On November 14, 2022, Eliem Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2022. A copy of such press release is attached to this Current Report as Exhibit 99.1.

Item 7.01. Regulation FD Disclosure.

A copy of a slide presentation that the Company will use at investor conferences and presentations is attached to this Current Report as Exhibit 99.2 and is incorporated herein solely for purposes of this Item 7.01 disclosure.

The information in Items 2.02 and 7.01 (including Exhibits 99.1 and 99.2) are being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether filed before or after the date hereof and regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.



Exhibit
Number                                    Description
 99.1       Press release of Eliem Therapeutics, Inc., dated November 14, 2022
 99.2       Investor Presentation dated November 14, 2022
  104     Cover Page Interactive Data File (embedded within the Inline XBRL document)








                                       1

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses